Roscovitine inhibits ERK1/2 activation induced by angiotensin II in vascular smooth muscle cells

FEBS Letters

Volumn 582, Issue 2, 2008, Pages 243-248

  Li, Ai Ying ^a   Han, Mei ^a   Zheng, Bin ^a   Wen, Jin Kun ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin II; c Jun; Extracellular signal regulated kinase1 2; Roscovitine; Vascular smooth muscle cell

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANGIOTENSIN II; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN C JUN; ROSCOVITINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA BINDING; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; BASE SEQUENCE; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; DNA PRIMERS; ENZYME ACTIVATION; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PURINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 38049049816     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2007.12.011     Document Type: Article

References (22)

1. Mohapatra S., Chu B., Wei S., Djeu J., Epling-Burnette P.K., Loughran T., Jove R., and Pledger W.J. Roscovitine inhibits stat5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2. Cancer Res. 63 (2003) 8523-8530
2. Whittaker S.R., Walton M.I., Garrett M.D., and Workman P. The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res. 64 (2004) 262-272
3. Ljungman M., and Paulsen M.T. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol. Pharmacol. 60 (2001) 785-789
4. Yan Z., Chi P., Bibb J.A., Ryan T.A., and Greengard P. Roscovitine: a novel regulator of P/Q-type calcium channels and transmitter release in central neurons. J. Physiol. 540 (2002) 761-770
5. Han M., Wen J.K., Zheng B., Cheng Y.H., and Zhang C.X. Serum deprivation results in redifferentiation of human umbilical vascular smooth muscle cells. Am. J. Physiol. Cell Physiol. 291 (2006) C50-C58
6. Zhao Y.L., Liu J., Li L., Liua L.M., and Wu L.L. Role of Ras/PKC∼/MEK/ERK1/2 signaling pathway in angiotensin II-induced vascular smooth muscle cell proliferation. Regul. Pep. 128 (2005) 43-50
7. Wen J.K., Han M., and Liu D. Molecular cloning and characterization of the promoter region of the inducible nitric oxide synthase gene of the rat. Biochemistry (Mosc.) 65 (2000) 1327-1330
8. Li J.J., Han M., Wen J.K., and Li A.Y. Osteopontin stimulates vascular smooth muscle cell migration by inducing FAK phosphorylation and ILK dephosphorylation. Biochem. Biophys. Res. Commun. 356 (2007) 13-19
9. Li A.Y., Wen J.K., and Han M. Role of AP-1 activation in regulation of angiotensinogen gene expression induced by Ang II. Prog. Biochem. Biophys. 33 (2006) 775-780
10. Nie L., Han M., and Wen J.K. Expression and regulation of vasodilative and vasoconstrictive peptides in vascular smooth muscle cells. Chin. J. Biochem. Mol. Biol. 21 (2005) 94-100
11. Eguchi S., and Inagami T. Signal transduction of angiotensin II type 1 receptor through receptor tyrosine kinase. Regul. Pept. 91 (2000) 13-20
12. 2-induced egr-1, fra-1, and c-jun gene expression is mediated by tyrosine kinase in aortic smooth muscle cells. Free Radic. Biol. Med. 29 (2000) 736-746
13. McClue S.J., Blake D., Clarke R., Cowan A., Cummings L., Fisher P.M., MacKenzie M., Melville J., Stewart K., Wang S., Zhelev N., Zheleva D., and Lane D.P. In vitro and in vivo antitumor properties of the cyclin-dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer 102 (2002) 463-468
14. Mgbonyebi O.P., Russo J., and Russo I.H. Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Cancer Res. 15 (1999) 1903-1910
15. O'Sullivana M., Scotta S.D., McCarthya N., Figga N., Shapirob L.M., Kirkpatrickc P., and Bennetta M.R. Differential cyclin E expression in human instent stenosis smooth muscle cells identifies targets for selective anti-restenosis therapy. Cardiovasc. Res. 60 (2003) 673-683
16. Kyaw M., Yoshizumi M., Tsuchiya K., Kirima K., and Tamaki T. Antioxidants inhibit JNK and p38 MAPK activation but not ERK1/2 activation by angiotensin II in rat aortic smooth muscle cells. Hypertens. Res. 24 (2001) 251-261
17. Wilkie N., Morton C., Ng L.L., and Boarder M.R. Stimulated mitogen activated protein kinase is necessary but not sufficient for the mitogenic response to angiotensin II. A role for phospholipase D. J. Biol. Chem. 271 (1996) 32447-32453
18. Zhou C.H., Qian Z.Y., Zheng S.G., and Xiang M. ERK1/2 pathway is involved in the inhibitory effect of crocetin on angiotensin II-induced vascular smooth muscle cell proliferation. Eur. J. Pharmacol. 535 (2006) 61-68
19. Atanasova G., Jans R., Zhelev N., Mitev V., and Poumay Y. Effects of the cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) on the physiology of cultured human keratinocytes. Biochem. Pharmacol. 70 (2005) 824-836
20. Vogt P.K., and Bos T.J. Jun: oncogene and transcription factor. Adv. Cancer Res. 55 (1990) 1-35
21. Hirai S., Bourachot B., and Yaniv M. Both Jun and Fos contribute to transcription activation by the heterodimer. Oncogene 5 (1990) 39-46
22. Angel P., Hattori K., Smeal T., and Karin M. The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell 55 (1988) 875-885